Scopolamine transdermal (availability varies) — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Motion sickness

• Meclizine

Also listed for Nausea from Motion Sickness

• Meclizine 12.5/25 mg tabs

About Scopolamine transdermal (availability varies)

Scopolamine transdermal patches offer powerful relief from motion sickness and post-operative nausea, but understanding their availability and cost can often be a challenge. At TheDrugClub, we believe essential medications should be both accessible and affordable. The scopolamine transdermal patch is a highly effective medication designed to prevent the discomfort of motion sickness and to manage post-operative nausea and vomiting (PONV). Whether you're planning a cruise, prone to car sickness, or preparing for surgery, this small, discreet patch can make a significant difference in your comfort and well-being. ### What Does Scopolamine Transdermal Treat? Primarily, scopolamine transdermal is prescribed for two main conditions: motion sickness and post-operative nausea and vomiting. For motion sickness, it's often applied hours before travel, providing continuous protection for up to three days. For PONV, it's typically applied the evening before or morning of surgery, helping to mitigate the often-unpleasant side effects of anesthesia and recovery. ### How Does It Work? Scopolamine works by acting on the central nervous system. It belongs to a class of drugs called anticholinergics, which block the action of a neurotransmitter called acetylcholine. In the context of motion sickness and nausea, scopolamine affects specific pathways in the brain that are responsible for processing signals related to balance and vomiting. By calming these pathways, it effectively prevents the symptoms of nausea, dizziness, and vomiting. The transdermal patch delivers the medication slowly and steadily through the skin, ensuring a consistent therapeutic effect over an extended period. ### Typical Costs and Availability Challenges

Accessing scopolamine transdermal can sometimes present hurdles. The scopolamine transdermal availability varies due to factors like manufacturing schedules, supply chain demands, and whether generic versions are readily stocked. When it comes to cost, prices can fluctuate significantly depending on your insurance coverage, the pharmacy you use, and whether you receive a brand-name or generic version. Without insurance, a single patch or a pack of patches could range anywhere from $30 to over $100, making it a considerable expense for many, especially if needed regularly. Even with insurance, co-pays can still add up.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Scopolamine transdermal (availability varies) is approved for (FDA label)

Scopolamine transdermal system is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. Scopolamine transdermal system is an anticholinergic indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. ( 1 ) post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Scopolamine transdermal (availability varies) (FDA label)

Transdermal system: a circular, flat, tan-colored transdermal system imprinted with “Scopolamine 1 mg/3 days” Transdermal system: 1 mg/3 days ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2a6f9aaf-a70a-481f-a82b-1dcaaadc185b. SPL document ID: 3baa2417-8daa-4253-89a4-fef4be344fc1. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Scopolamine transdermal (availability varies) (FDA label)

Most common adverse reactions are: Motion Sickness (>15%): dry mouth, drowsiness, blurred vision and dilation of the pupils. ( 6.1 ) PONV (≥ 3%): dry mouth, dizziness, somnolence, agitation, visual impairment, confusion, mydriasis and pharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The following serious adverse reactions are described elsewhere in labeling: Acute Angle Closure Glaucoma [see Warnings and Precautions ( 5.1 )] Neuropsychiatric Adverse Reactions [see Warnings and Precautions ( 5.2 )] Eclamptic Seizures in Pregnant Women [see Warnings and Precautions ( 5.3 )] Gastrointestinal and Urinary Disorders [see Warnings and Precautions ( 5.4 )] Hyperthermia [see Warnings and Precautions ( 5.5 )] Drug Withdrawal/Post-Removal Symptoms [see Warnings and Precautions ( 5.6 )] Blurred Vision [see Warnings and Precautions ( 5.7 )] MRI Skin Burns [see Warnings and Precautions ( 5.8 )] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2a6f9aaf-a70a-481f-a82b-1dcaaadc185b. SPL document ID: 3baa2417-8daa-4253-89a4-fef4be344fc1. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Scopolamine transdermal (availability varies) (FDA label)

Scopolamine transdermal system is contraindicated in patients with: angle closure glaucoma [see Warnings and Precautions ( 5.1 )]. hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. Reactions have included rash generalized and erythema [see Adverse Reactions ( 6.2 ), Description ( 11 )] . Angle closure glaucoma. ( 4 , 6.2 ) Hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component of the formulation or delivery system. ( 4 , 7 )

Source: FDA prescribing information (DailyMed). Set ID: 2a6f9aaf-a70a-481f-a82b-1dcaaadc185b. SPL document ID: 3baa2417-8daa-4253-89a4-fef4be344fc1. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Scopolamine transdermal (availability varies) (FDA label)

Acute Angle Closure Glaucoma: Monitor for increased intraocular pressure in patients with open-angle glaucoma and adjust glaucoma therapy as needed. Discontinue if signs or symptoms of acute angle closure glaucoma develop. ( 5.1 ) Neuropsychiatric Adverse Reactions: May cause psychiatric and cognitive effects, seizures and impair mental and/or physical abilities. Monitor patients for new or worsening psychiatric symptoms during treatment and during concomitant treatment with other drugs that are associated with similar psychiatric effects. ( 5.2 , 7.1 ) Eclamptic Seizures in Pregnant Women: Avoid use in patients with severe preeclampsia. ( 5.3 ) Gastrointestinal and Urinary Disorders: Consider more frequent monitoring during treatment in patients suspected of having intestinal obstruction; patients with pyloric obstruction, patients with impeded urine flow or receiving other anticholinergic drugs.

Source: FDA prescribing information (DailyMed). Set ID: 2a6f9aaf-a70a-481f-a82b-1dcaaadc185b. SPL document ID: 3baa2417-8daa-4253-89a4-fef4be344fc1. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Scopolamine transdermal (availability varies) (FDA label)

Drugs Causing Central Nervous System (CNS) Adverse Reactions: Monitor patients for CNS adverse reactions (drowsiness, dizziness or disorientations). ( 7.1 ) Anticholinergic Drugs: Consider more frequent monitoring during treatment in patients receiving other anticholinergic drugs. ( 7.2 ) Oral Drugs Absorbed in the Stomach: Monitor for increased or decreased therapeutic effect of the oral drug. ( 7.3 ) Interaction with Gastric Secretion Test: Discontinue use of scopolamine transdermal system 10 days prior to testing. ( 7.4 ) 7.1 Drugs Causing Central Nervous System (CNS) Adverse Reactions The concurrent use of scopolamine transdermal system with other drugs that cause CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of scopolamine transdermal system [see Warnings and Precautions ( 5.2 )] . Either scopolamine transdermal system or the interacting drug should be chosen, depending on the importance of the drug to the patient.

Source: FDA prescribing information (DailyMed). Set ID: 2a6f9aaf-a70a-481f-a82b-1dcaaadc185b. SPL document ID: 3baa2417-8daa-4253-89a4-fef4be344fc1. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.